The US Food and Drug Administration (FDA) has taken action to authorize a wide variety of diagnostics for SARS-CoV-2 under the "Emergency Use Authorization" policy.
The authorization lasts as long as the relevant public health problem, but is not a full FDA approval.
Rodney E. Rohde, a clinical laboratory specialist at Texas State University, helps break down how carefully these releases need to be read in order for scientists from other fields to parse them for useful information.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
